Compare Amgen, Inc. (AMGN) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs NextEra Energy, Inc. — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while NextEra Energy, Inc. trades at $87.97 (market cap $183.45B). The key difference: Amgen, Inc. and NextEra Energy, Inc. are close in size by market cap, and NextEra Energy, Inc. pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| AMGN | NEE | |
|---|---|---|
Market Cap | $196.12B | $183.45B |
Sector | Health | Utilities |
52-Week High | $388.16 | $97.88 |
52-Week Low | $271.18 | $69.77 |
Enterprise Value | $241.41B | $285.85B |
Dividend Yield | 2.77% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
NextEra Energy (NEE) trades at $87.96, up 0.99% on the day, with a bearish technical signal despite positive earnings momentum. The company reported strong Q1 2026 EPS of $1.09, beating expectations, and maintains robust profitability with a 29.37% net income margin. Recent news highlights the Dominion deal as a major catalyst, while analyst consensus remains strongly bullish with a $104.43 price target representing 19% upside potential.
NEE presents a compelling long-term investment opportunity driven by clean energy demand and strategic partnerships, though near-term technical weakness and rising debt levels warrant caution. The stock's current valuation at 22.32x P/E appears reasonable given growth prospects, but regulatory uncertainty from recent acquisitions and capital-intensive operations pose execution risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
